Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 3
2000 3
2001 4
2002 2
2003 7
2005 2
2006 10
2007 11
2008 11
2009 6
2010 8
2011 3
2012 12
2013 8
2014 4
2015 2
2016 1
2017 2
2019 3
2020 2
2021 3
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Lixivaptan: a novel vasopressin receptor antagonist.
Ku E, Nobakht N, Campese VM. Ku E, et al. Expert Opin Investig Drugs. 2009 May;18(5):657-62. doi: 10.1517/13543780902889760. Expert Opin Investig Drugs. 2009. PMID: 19379124 Review.
Studies so far have demonstrated that lixivaptan is efficacious in the correction of hyponatremia in SIADH, heart failure and liver cirrhosis with ascites, and few adverse effects have been noted. Thus, lixivaptan remains a promising therapeutic modality for the tre …
Studies so far have demonstrated that lixivaptan is efficacious in the correction of hyponatremia in SIADH, heart failure and liver c …
Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
Ghali JK, Zmily HD, Farah JO, Daifallah S. Ghali JK, et al. IDrugs. 2010 Nov;13(11):782-92. IDrugs. 2010. PMID: 21046526 Review.
The therapeutic benefits of lixivaptan are being evaluated in patients with conditions that are associated with water excess and hyponatremia. ...Ongoing phase III trials will determine the role of lixivaptan in the management of hyponatremia, especially when associ …
The therapeutic benefits of lixivaptan are being evaluated in patients with conditions that are associated with water excess and hypo …
Hyponatremia in Heart Failure: Pathogenesis and Management.
Rodriguez M, Hernandez M, Cheungpasitporn W, Kashani KB, Riaz I, Rangaswami J, Herzog E, Guglin M, Krittanawong C. Rodriguez M, et al. Curr Cardiol Rev. 2019;15(4):252-261. doi: 10.2174/1573403X15666190306111812. Curr Cardiol Rev. 2019. PMID: 30843491 Free PMC article. Review.
In recent years, a few strategies, such as AVP antagonists (Tolvaptan, Conivaptan, and Lixivaptan), and hypertonic saline in addition to loop diuretics, have been proposed as potentially promising treatment options for this condition. ...
In recent years, a few strategies, such as AVP antagonists (Tolvaptan, Conivaptan, and Lixivaptan), and hypertonic saline in addition …
The potential role for lixivaptan in heart failure and in hyponatremia.
Zmily HD, Khan NS, Daifallah S, Ghali JK. Zmily HD, et al. Expert Opin Investig Drugs. 2011 Jun;20(6):831-48. doi: 10.1517/13543784.2011.579102. Epub 2011 May 9. Expert Opin Investig Drugs. 2011. PMID: 21548825 Review.
Stimulation of arginine vasopressin (AVP) plays an important role in the development of both hypervolemia and hyponatremia. Lixivaptan is a selective vasopressin type 2 (V(2)) receptor antagonist that has been demonstrated to have the ability to induce aquaresis, the elect …
Stimulation of arginine vasopressin (AVP) plays an important role in the development of both hypervolemia and hyponatremia. Lixivaptan …
Evaluation of lixivaptan in euvolemic and hypervolemic hyponatremia and heart failure treatment.
Zmily HD, Alani A, Ghali JK. Zmily HD, et al. Expert Opin Drug Metab Toxicol. 2013 May;9(5):645-55. doi: 10.1517/17425255.2013.783566. Epub 2013 Apr 9. Expert Opin Drug Metab Toxicol. 2013. PMID: 23570283 Review.
INTRODUCTION: Lixivaptan is a selective vasopressin type 2 (V2) receptor antagonist that induces aquaresis, the electrolytes sparing excretion of water. ...AREAS COVERED: The authors review original publications on lixivaptan and summarize their findings. Specifical …
INTRODUCTION: Lixivaptan is a selective vasopressin type 2 (V2) receptor antagonist that induces aquaresis, the electrolytes sparing …
Treatment of hyponatremia: the role of lixivaptan.
Liamis G, Filippatos TD, Elisaf MS. Liamis G, et al. Expert Rev Clin Pharmacol. 2014 Jul;7(4):431-41. doi: 10.1586/17512433.2014.911085. Epub 2014 Apr 28. Expert Rev Clin Pharmacol. 2014. PMID: 24766294 Review.
The present review considers the role of vasopressin receptor inhibitors (vaptans), focusing on lixivaptan, in the treatment of patients with euvolemic or hypervolemic hyponatremia. Lixivaptan is an oral selective V2 receptor inhibitor, which produces a significantl …
The present review considers the role of vasopressin receptor inhibitors (vaptans), focusing on lixivaptan, in the treatment of patie …
Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells.
Di Mise A, Venneri M, Ranieri M, Centrone M, Pellegrini L, Tamma G, Valenti G. Di Mise A, et al. Int J Mol Sci. 2019 Dec 26;21(1):183. doi: 10.3390/ijms21010183. Int J Mol Sci. 2019. PMID: 31888044 Free PMC article.
Consistent with this finding, real-time fluorescence kinetic measurements demonstrated that lixivaptan prevented dDAVP-induced increase in osmotic water permeability. These data represent the first detailed demonstration of the central role of AQP2 blockade in the aquareti …
Consistent with this finding, real-time fluorescence kinetic measurements demonstrated that lixivaptan prevented dDAVP-induced increa …
Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia.
Abraham WT, Hensen J, Gross PA, Bichet DG, Josiassen RC, Chafekar DS, Orlandi C; LIBRA Study Group. Abraham WT, et al. Kidney Int. 2012 Dec;82(11):1223-30. doi: 10.1038/ki.2012.275. Epub 2012 Aug 29. Kidney Int. 2012. PMID: 22932119 Free article. Clinical Trial.
Of them, 52 were randomized to receive placebo and 54 received 50 mg lixivaptan once daily and were then titrated to receive 25-100 mg once daily depending on serum sodium concentration. ...Thus, lixivaptan safely and effectively corrects serum sodium concentrations …
Of them, 52 were randomized to receive placebo and 54 received 50 mg lixivaptan once daily and were then titrated to receive 25-100 m …
Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia.
Abraham WT, Decaux G, Josiassen RC, Yagil Y, Kopyt N, Thacker HP, Mannelli M, Bichet DG, Orlandi C; HARMONY Study Group. Abraham WT, et al. Kidney Int. 2012 Dec;82(11):1215-22. doi: 10.1038/ki.2012.274. Epub 2012 Aug 29. Kidney Int. 2012. PMID: 22932122 Free article. Clinical Trial.
A significantly greater proportion of patients that received lixivaptan achieved normal serum sodium (39.4%) by day 7 relative to placebo (12.2%). Overall, lixivaptan was considered safe and well-tolerated. Thus, oral lixivaptan can be safely initiated in the …
A significantly greater proportion of patients that received lixivaptan achieved normal serum sodium (39.4%) by day 7 relative to pla …
Lixivaptan and hyponatremia.
Ring T. Ring T. Kidney Int. 2013 Jun;83(6):1205-6. doi: 10.1038/ki.2013.39. Kidney Int. 2013. PMID: 23728012 Free article. No abstract available.
107 results